RxDoctor Payments Data

Michael Metzger, MD

Cardiovascular Disease · Delray Beach, FLNPI 1235253899

Payments from drug & device makers

$52,704in general payments, 2019–2025

Across 944 payments — averaging $55.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$18K
  • Inari Medical, Inc.$14K
  • Penumbra, Inc.$2K
  • Abbott$2K
  • Shockwave Medical, Inc$1K
  • Amgen$1K
  • plus $14K from 53 others

What the payments were for

  • Consulting fees$12,40024%
  • Speaking & faculty fees$17,00032%
  • Travel & lodging$2,0244%
  • Food & beverage$21,17640%
  • Education$1030%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Boston Scientific29$17,852
Inari Medical, Inc.18$13,943
Penumbra, Inc.16$2,407
Abbott89$2,273
Shockwave Medical, Inc18$1,157
Amgen77$1,131
Philips North America LLC6$1,096
Johnson & Johnson108$1,073
AstraZeneca63$1,026
Pfizer57$790
Novartis53$785
Abiomed22$742
E.r. Squibb & Sons, L.L.C.36$633
Actelion Pharmaceuticals US, Inc.27$631
Amarin Pharma, Inc.35$592
Boehringer Ingelheim28$589
Merck26$486
Sanofi-aventis U.S. LLC23$461
Cvrx, Inc.28$431
Medtronic(2 entities)12$370
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)31$350
Kestra Medical Technology Services, Inc.12$308
Heartflow, Inc.5$296
Impulse Dynamics (USA) Inc.4$292
Bard Peripheral Vascular, Inc.7$274
Kowa Pharmaceuticals America, Inc.14$259
Cook Medical LLC2$233
Edwards Lifesciences3$216
Alnylam Pharmaceuticals Inc.9$190
Lundbeck LLC9$173
Novo Nordisk5$129
Esperion Therapeutics, Inc.7$112
Chiesi USA, Inc.7$111
Bayer6$105
United Therapeutics Corporation4$103
Bolton Medical Inc1$99
Bridgebio Pharma, Inc.5$98
Kiniksa Pharmaceuticals International, PLC3$96
Tactile Systems Technology Inc5$90
Kiniksa Pharmaceuticals, Ltd.4$82
Regeneron Healthcare Solutions, Inc.5$77
Cardiva Medical, Inc.2$71
BD2$60
Lexicon Pharmaceuticals, Inc.3$58
GE HealthCare2$44
Biotronik Inc.2$43
Stryker1$36
Braemar Manufacturing, LLC1$30
Vital Connect, Inc1$24
ZOLL Circulation Inc2$22
Agepha Pharma FZ LLC1$20
Akcea Therapeutics, Inc.1$20
CSL Behring1$19
Gilead1$18
Arbor Pharmaceuticals, Inc.1$18
Cardinal Health 200 LLC1$16
Biocompatibles, Inc.1$16
Cordis US CORP.1$16
G Medical Diagnostic Services, Inc.1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$52,704 in reported general payments places this provider in the 85th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$2,299,249
Medicare patients
2,684
Services billed
19,059

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban415$470,433
EliquisApixaban311$398,345
EntrestoSacubitril/Valsartan152$211,482
Repatha SureclickEvolocumab134$126,076
BrilintaTicagrelor93$91,418
MultaqDronedarone Hcl38$59,811
Praluent PenAlirocumab46$30,214
WegovySemaglutide19$25,472
FarxigaDapagliflozin Propanediol25$23,778
OzempicSemaglutide15$16,089
VascepaIcosapent Ethyl15$15,511
Repatha SyringeEvolocumab12$13,116
Ranolazine ErRanolazine71$12,304
LivaloPitavastatin Calcium17$11,925
Icosapent Ethyl17$11,511

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$1,073$470,433415 claims
PfizerEliquis$790$398,345311 claims
NovartisEntresto$785$211,482152 claims
AstraZenecaBrilinta, Farxiga$1,026$115,196118 claims
Sanofi-aventis U.S. LLCMultaq$461$59,81138 claims
Novo NordiskWegovy, Ozempic$129$41,56234 claims
Kowa Pharmaceuticals America, Inc.Livalo$259$11,92517 claims
Arbor Pharmaceuticals, Inc.Edarbi$18$7,38316 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Delray Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →